Immunological responses in a Chlamydia trachomatis vaccine trial
A vaccine against chlamydia is widely agreed to be an essential public health control measure for both sexually transmitted and ocular infections.1 There have been many decades and much investment in research towards a chlamydial vaccine, and it has been quite some time between phase 1 trials; until recently this antigen was shown to be safe.2